Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, Inusa B, Rees DC, Small DS, Gupta N, Yao S, Heeney M, Kanter J. Jakubowski JA, et al. Among authors: hoppe cc. Thromb Haemost. 2017 Feb 28;117(3):580-588. doi: 10.1160/TH16-09-0731. Epub 2016 Dec 8. Thromb Haemost. 2017. PMID: 27929203 Clinical Trial.
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, Brown PB, Rees DC, Heeney MM. Hoppe CC, et al. Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24. Pediatr Blood Cancer. 2016. PMID: 26402148 Clinical Trial.
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators. Heeney MM, et al. Among authors: hoppe cc. N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8. N Engl J Med. 2016. PMID: 26644172 Free article. Clinical Trial.
Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM, Hoppe CC, Rees DC. Heeney MM, et al. Among authors: hoppe cc. N Engl J Med. 2016 Jul 14;375(2):185-6. doi: 10.1056/NEJMc1603499. N Engl J Med. 2016. PMID: 27410930 No abstract available.
Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.
Kanter J, Heath LE, Knorr J, Agbenyega ET, Colombatti R, Dampier C, Hassab H, Manwani D, Robitaille N, Brown PB, Jakubowski JA, Yao S, Hoppe C. Kanter J, et al. Br J Haematol. 2019 Mar;184(6):1058-1061. doi: 10.1111/bjh.15250. Epub 2018 Apr 20. Br J Haematol. 2019. PMID: 29676449 Free article. No abstract available.
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. Vichinsky E, et al. Among authors: hoppe cc. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. N Engl J Med. 2019. PMID: 31199090 Clinical Trial.
Definitions of the phenotypic manifestations of sickle cell disease.
Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ; Investigators, Comprehensive Sickle Cell Centers. Ballas SK, et al. Am J Hematol. 2010 Jan;85(1):6-13. doi: 10.1002/ajh.21550. Am J Hematol. 2010. PMID: 19902523 Free PMC article.
75 results